New Sponsor Week 32 -2025 SSS
sponsor Category Week 32 -2025 SSS SSS
week 40 Sponsor sss sss
sponsor Category Week 32 -2025 SSS SSS, week 40 sponsor Category sss
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Day One AM
Morning Check-in & Coffee
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed et nulla sit amet justo volutpat placerat. Cras ac sapien porta, facilisis dolor aliquet, efficitur justo. Maecenas et condimentum libero, ut porttitor ligula. Nunc velit felis, imperdiet non semper eget, sagittis eget turpis. Nulla nec purus elit. Nullam finibus ipsum vel sapien bibendum, et molestie lacus…
Chair’s Opening Remarks
Speaker
-
Nicholas Valiante
Co-Founder & Chief Scientific Officer - Innovac Therapeutics
CXOs’ Panel Discussion: Unlocking the Next Frontiers of mRNA-Based Vaccines & Therapeutics to Ensure Better Drugs Reach Patients Faster
What do you think are the top 3 opportunities/near future wins for the mRNA field? Given your role in the C-suite, what are the biggest challenges you face on a day-to-day basis and what kind of decisions do you have to make? Given your role and affiliation, how do you view the market consolidation and…
Speakers
-
Nicholas Valiante
Co-Founder & Chief Scientific Officer - Innovac Therapeutics -
Thaminda Ramanayake
Chief Business Officer - CureVac -
Nathaniel Wang
Chief Executive Officer - Replicate Bioscience -
Sophia Lugo
CEO - Radar Therapeutics -
Igor Matushansky
Chief Medical Officer - Sail Biomedicines -
Andrew Allen
Chief Executive Officer - Gritstone Bio
Clinical Safety & Impact of RNA Cell Therapy in Patients with Myasthenia Gravis
RNA cell therapy allows transient expression of chimeric antigen receptor in T cells, enabling therapies that do not require lymphodepletion and eliminate risk of cancerous transformation Expanding the potential of cell therapies to patients with autoimmunity, where the risk-benefit ratio is more stringent than in oncology Sharing our latest data from clinical trials using our…
Speaker
-
Christopher Jewell
Chief Scientific Officer - Cartesian Therapeutics
mRNA Therapeutics: Riding the Next Wave in Biotech
mRNA Therapeutics: Riding the Next Wave in Biotech Eras that define the evolution of biotechnology The latest and the greatest in the world of mRNA – the next frontier in biotech The bottlenecks in clinical translation and how Resilience is striving to address those challenges
Speaker
-
Aalok Shah
Director of Process Development - Resilience
Morning Networking Break
Day One Track A, PM
Day One Track A, PM, Heading 1
Session 1 Day One Track A, PM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
David Richardson
SEO Influencer - Search Ltd
Session 2 Day One Track A, PM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Kevin Nguyen
Head of Business Development - Pacific Partnerships
Day One Track B, PM
Session 2 Day One Track B, PM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Harold Johnson
CEO - Acme Ltd
Day Two AM
Test Track
Lorem Ipsum has been the industry’s standard dummy text ever since the 1500 when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with…
Speakers
-
Alisa Zhilin Roth
Senior Scientist, In vitro & Mechanism - Sanofi -
Allen Horhota
Head of Platform - Orna Therapeutics
Day Two Track A, AM
Day Two Track A, AM, Heading 1
Session 1 Day Two Track A, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Michael Thompson
Project Manager - PLC Inc.
Session 2 Day Two Track A, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Emily Carter
Chief Financial Officer - Global Dynamics
Day Two Track B, AM
Day Two Track B, AM, Heading 2
Session 3 Day Two Track B, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Angela Harris
Director of Marketing - Synergy Strategies
Session 4 Day Two Track B, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Angela Harris
Director of Marketing - Synergy Strategies
Day Two
Test Track
Lorem Ipsum has been the industry’s standard dummy text ever since the 1500 when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with…
Speakers
-
Alisa Zhilin Roth
Senior Scientist, In vitro & Mechanism - Sanofi -
Allen Horhota
Head of Platform - Orna Therapeutics
Day Two Track A, AM, Heading 1
Session 1 Day Two Track A, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Michael Thompson
Project Manager - PLC Inc.
Day Two Track C, AM, Heading 1
Session 1 Day Two Track C, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Emily Carter
Chief Financial Officer - Global Dynamics
Session 2 Day Two Track A, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Emily Carter
Chief Financial Officer - Global Dynamics
Session 2 Day Two Track C, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Angela Harris
Director of Marketing - Synergy Strategies
Day Two Track B, AM, Heading 2
Day Two Track C, AM, Heading 2
Session 3 Day Two Track B, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Angela Harris
Director of Marketing - Synergy Strategies
Session 3 Day Two Track C, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Marcus Johnson
Senior Project Manager - Innovative Solutions
Session 4 Day Two Track B, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Angela Harris
Director of Marketing - Synergy Strategies
Session 4 Day Two Track C, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Sarah Lee
Chief Strategy Officer - Visionary Ventures
Day One Track A - Discovery
Unlocking the Power of Next Generation Base Editors & Replicating mRNA for Pushing the Frontiers of mRNA
Advancing Next Generation Gene Editing with Beam Therapeutics’ Proprietary Next Generation Base Editor
Using mRNA for targeted delivery of a single nucleotide base editor to cure genetic ailments Preventing dsDNA breaks for more efficient and predictable gene editing Revealing pre-clinical data on ex vivo and in vivo p
Speaker
-
Luis Barrera
Senior Vice President, Data Sciences - Beam Therapeutics
Multimodal Support of mRNA Therapeutic Development
Download the event guide for full session details.
Speaker
-
Wayne Doyle
Head of Platform - Eclipsebio
Enabling Single-Dose, Multivalent Vaccination Against Pathogens of High Consequence Using a Muscle-Localizing NanocarrierFormulated Replicating mRNA
Download the event guide for full session details.
Speaker
-
Jesse Erasmus
Director, Virology - HDT Bio
Accessing a Vast Design Space with a Modular High Throughput Platform for RNA Therapeutics & Vaccines
Download the event guide for full session details.
Speaker
-
Stephanie Khan
Director, Business Development - Ginkgo Bioworks
Day One Track B - Translation
Widening the Scope of mRNA with circRNA Vaccines & Therapeutics to Treat Infectious & Oncological Diseases
Introducing Orbital’s circRNA Vaccine Platform as a Novel Alternative to a Linear Vaccine
Download the event guide for full session details.
Speaker
-
Gilles Besin
Chief Scientific Officer - Orbital Therapeutics
Reduction of LNP-Associated Inflammation with Use of Biodegradable Lipids
Ionizable lipids are known to present varying degrees of immunotoxicity. Understanding the role of key cellular mediators such as the NLRP3 inflammasome in this context will be key to developing the next generation of safe, well tolerated non-viral delivery systems Our work on biodegradable ionizable lipids has indicated that tissue resident macrophages are key mediators…
Speaker
-
Syed Reza
Scientific & Sales Consultant - NOF CORPORATION
In vivo panCARTM Therapy Using Circular RNA for the Treatment of B Cell Malignancies in Oncology & Autoimmune Disease
Download the event guide for full session details.
Speaker
-
Robert Mabry
Chief Scientific Officer - Orna Therapeutics
Lunch Networking Break
Supercharging the Translation of Novel mRNA Therapeutics to Combat Cancer & Advance Regenerative Medicine
Advancing Novel mRNA Therapeutics Through Discovery & Development Phases
Download the event guide for full session details.
Speaker
-
Sam Deutsch
Chief Scientific Officer - Nutcracker Therapeutics
mRNA-Based Transcription Factor Delivery to In Vivo Disease Models
Download the event guide for full session details.
Speaker
-
Hanae Toyonoga
Manager, Discovery Accelerator - Astellas Pharma
Advancing Onco-Selective mRNA Therapeutics with Kernal’s KR-335 Program to Kill Tumor Cells
Download the event guide for full session details.
Speaker
-
Manfred Kraus
Vice-President, Head of R&D Therapeutics - Kernal Biologics
Afternoon Networking Break & Poster Session
Broadening the Horizons of mRNA Through Next Generation Replicating Vaccines & Therapeutics
Improvements to the Self-AAmplifying RNA Platform for Safer & More Effective Vaccines & Therapeutics
Download the event guide for full session details.
Speaker
-
Peter Berglund
Chief Scientific Officer - HDT Bio
Presenting Johnson & Johnson’s Discovery & Pre-Clinical Work with saRNA for Vaccine & Therapeutic Applications
Download the event guide for full session details.
Speaker
-
Rachel Groppo
Director, Lead Self-Amplifying RNA Team - Johnson & Johnson Innovative Medicine
Day One Track C - Clinical Development
Advancing Neoantigen-Based mRNA Medicines in the Clinic to Effectively Treat Oncological Indications
Revealing Key Clinical Findings from Moderna’s Individualized Neoantigen Therapy Against Melanoma
Download the event guide for full session details.
Speaker
-
Laureen Ojalvo
Executive Medical Director, Oncology - Moderna
Mitigating Risk Through Development & Engineering Runs When Transitioning from Preclinical to Clinical Manufacturing
Download the event guide for full session details.
Speaker
-
Evan Myers
Associate Director, Process Development - TriLink BioTechnologies
Neoantigen Immunotherapy for Solid Tumors: Molecular Responses & Clinical Benefit in Late-Stage Patients
Download the event guide for full session details.
Speaker
-
Andy Ferguson
Vice President, Clinical Science - Gritstone Bio
Lunch Networking Break
Supercharging the saRNA Vaccine Platforms Against Infectious Diseases to Improve Patient Outcomes
Next Generation Self-Replicating RNA (srRNA) Drives Substantial Improvement in Infectious Disease Vaccines
Download the event guide for full session details.
Speaker
-
Nathaniel Wang
Chief Executive Officer - Replicate Bioscience
Strategies for Navigating the Complexity & Diversity of RNALipid Nanoparticles
Download the event guide for full session details.
Speaker
-
Ian Johnston
Field Application Scientist - Cytiva
Comparing a Second-Generation saRNA Flu Vaccine with a Traditional mRNA Flu Vaccine
Download the event guide for full session details.
Speaker
-
Cheng Chang
Associate Director, RNA Platform - CSL
Afternoon Networking Break & Poster Session
Revealing the Latest Next Generation Infectious Disease Vaccines to Open Up New Frontiers for mRNA
Beyond Respiratory mRNA Vaccines: Moderna’s Norovirus mRNA Vaccine Candidates
Download the event guide for full session details.
Speaker
-
Till Schoofs
Director, Clinical Development, Infectious Diseases - Moderna
Diving into the Analytical Characterization of in vitro Transcribed mRNAs
Download the event guide for full session details.
Speaker
-
Julien Camperi, Ph.D.
Technical Development Principal Scientist - Gene & Cell Therapy - Genentech, A Member of the Roche Group
Day One Track D - CMC
Developing a Strategic Platform Approach to Ensure Robust Manufacturing Processes for mRNA-Based Drugs
Establishing an mRNA Vaccine Platform to Effectively Support a Broad Vaccine & Therapeutics Drug Portfolio
Download the event guide for full session details.
Speaker
-
Joshua DiNapoli
Global Project Head, mRNA Platform Development - Sanofi
Trehalose & Sucrose: Essential Components of Platform Biopharma Formulations & COVID-19 Applications
Download the event guide for full session details.
Speaker
-
Sudhakar Voruganti
Business Development Director - Pfanstiehl
Leveraging Historic Know-How to Establish a Strategic Internal End-to-End Nucleic Acid Production Platform
Download the event guide for full session details.
Speaker
-
Emily Wen
Senior Principal Scientist - Merck & Co
Quality in mRNA Therapeutics – How to Achieve this in Practice
Download the event guide for full session details.
Speaker
-
Philip Challis
Senior Vice President of Manufacturing - etehrna
Lunch Networking Break
Mission Possible: Showcasing Breakthrough mRNA Vaccine Initiatives to Establish Rapid Responses to Viral Pathogens
RNA Vaccine Innovations for CEPI’s 100 Days Mission
Download the event guide for full session details.
Speaker
-
Dimki Patel
CMC Program Leader - CEPI
Maximizing Success in mRNA Manufacturing: Key Considerations for Analytical Characterization
Download the event guide for full session details.
Speaker
-
Eunseo Ency Lee
Lead Scientist, mRNA Manufacturing Group - Samsung Biologics
BAXERNA: On a Mission to Develop Novel Bacterial mRNA Vaccines
Download the event guide for full session details.
Speaker
-
Lyudmila Kovalchuke
Project Manager - VIB-UGent
Afternoon Networking Break & Poster Session
Flash Poster Presentations
Flash Poster Presentations
Jeffrey Ulmer, President, TechImmune LLC Rachel Young, Graduate Research Fellow, Rowan University Download the event guide for full session details.
Fine-Tuning mRNA Production with Innovative Enzymes & Raw Materials for Faster Synthesis
Democratizing mRNA Therapeutics with Novel Cap Analogs & Modified NTPs
Download the event guide for full session details.
Speaker
-
May Guo
Chief Commercial Officer - Areterna
Day One PM
Drinks Reception Hosted by Thermo Fisher
Day One
Morning Check-in & Coffee
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed et nulla sit amet justo volutpat placerat. Cras ac sapien porta, facilisis dolor aliquet, efficitur justo. Maecenas et condimentum libero, ut porttitor ligula. Nunc velit felis, imperdiet non semper eget, sagittis eget turpis. Nulla nec purus elit. Nullam finibus ipsum vel sapien bibendum, et molestie lacus…
Chair’s Opening Remarks
Speaker
-
Nicholas Valiante
Co-Founder & Chief Scientific Officer - Innovac Therapeutics
CXOs’ Panel Discussion: Unlocking the Next Frontiers of mRNA-Based Vaccines & Therapeutics to Ensure Better Drugs Reach Patients Faster
What do you think are the top 3 opportunities/near future wins for the mRNA field? Given your role in the C-suite, what are the biggest challenges you face on a day-to-day basis and what kind of decisions do you have to make? Given your role and affiliation, how do you view the market consolidation and…
Speakers
-
Nicholas Valiante
Co-Founder & Chief Scientific Officer - Innovac Therapeutics -
Thaminda Ramanayake
Chief Business Officer - CureVac -
Nathaniel Wang
Chief Executive Officer - Replicate Bioscience -
Sophia Lugo
CEO - Radar Therapeutics -
Igor Matushansky
Chief Medical Officer - Sail Biomedicines -
Andrew Allen
Chief Executive Officer - Gritstone Bio
Clinical Safety & Impact of RNA Cell Therapy in Patients with Myasthenia Gravis
RNA cell therapy allows transient expression of chimeric antigen receptor in T cells, enabling therapies that do not require lymphodepletion and eliminate risk of cancerous transformation Expanding the potential of cell therapies to patients with autoimmunity, where the risk-benefit ratio is more stringent than in oncology Sharing our latest data from clinical trials using our…
Speaker
-
Christopher Jewell
Chief Scientific Officer - Cartesian Therapeutics
mRNA Therapeutics: Riding the Next Wave in Biotech
mRNA Therapeutics: Riding the Next Wave in Biotech Eras that define the evolution of biotechnology The latest and the greatest in the world of mRNA – the next frontier in biotech The bottlenecks in clinical translation and how Resilience is striving to address those challenges
Speaker
-
Aalok Shah
Director of Process Development - Resilience
Morning Networking Break
Developing a Strategic Platform Approach to Ensure Robust Manufacturing Processes for mRNA-Based Drugs
Advancing Neoantigen-Based mRNA Medicines in the Clinic to Effectively Treat Oncological Indications
Widening the Scope of mRNA with circRNA Vaccines & Therapeutics to Treat Infectious & Oncological Diseases
Unlocking the Power of Next Generation Base Editors & Replicating mRNA for Pushing the Frontiers of mRNA
Revealing Key Clinical Findings from Moderna’s Individualized Neoantigen Therapy Against Melanoma
Download the event guide for full session details.
Speaker
-
Laureen Ojalvo
Executive Medical Director, Oncology - Moderna
Establishing an mRNA Vaccine Platform to Effectively Support a Broad Vaccine & Therapeutics Drug Portfolio
Download the event guide for full session details.
Speaker
-
Joshua DiNapoli
Global Project Head, mRNA Platform Development - Sanofi
Advancing Next Generation Gene Editing with Beam Therapeutics’ Proprietary Next Generation Base Editor
Using mRNA for targeted delivery of a single nucleotide base editor to cure genetic ailments Preventing dsDNA breaks for more efficient and predictable gene editing Revealing pre-clinical data on ex vivo and in vivo p
Speaker
-
Luis Barrera
Senior Vice President, Data Sciences - Beam Therapeutics
Introducing Orbital’s circRNA Vaccine Platform as a Novel Alternative to a Linear Vaccine
Download the event guide for full session details.
Speaker
-
Gilles Besin
Chief Scientific Officer - Orbital Therapeutics
Mitigating Risk Through Development & Engineering Runs When Transitioning from Preclinical to Clinical Manufacturing
Download the event guide for full session details.
Speaker
-
Evan Myers
Associate Director, Process Development - TriLink BioTechnologies
Reduction of LNP-Associated Inflammation with Use of Biodegradable Lipids
Ionizable lipids are known to present varying degrees of immunotoxicity. Understanding the role of key cellular mediators such as the NLRP3 inflammasome in this context will be key to developing the next generation of safe, well tolerated non-viral delivery systems Our work on biodegradable ionizable lipids has indicated that tissue resident macrophages are key mediators…
Speaker
-
Syed Reza
Scientific & Sales Consultant - NOF CORPORATION
Multimodal Support of mRNA Therapeutic Development
Download the event guide for full session details.
Speaker
-
Wayne Doyle
Head of Platform - Eclipsebio
Trehalose & Sucrose: Essential Components of Platform Biopharma Formulations & COVID-19 Applications
Download the event guide for full session details.
Speaker
-
Sudhakar Voruganti
Business Development Director - Pfanstiehl
Enabling Single-Dose, Multivalent Vaccination Against Pathogens of High Consequence Using a Muscle-Localizing NanocarrierFormulated Replicating mRNA
Download the event guide for full session details.
Speaker
-
Jesse Erasmus
Director, Virology - HDT Bio
In vivo panCARTM Therapy Using Circular RNA for the Treatment of B Cell Malignancies in Oncology & Autoimmune Disease
Download the event guide for full session details.
Speaker
-
Robert Mabry
Chief Scientific Officer - Orna Therapeutics
Leveraging Historic Know-How to Establish a Strategic Internal End-to-End Nucleic Acid Production Platform
Download the event guide for full session details.
Speaker
-
Emily Wen
Senior Principal Scientist - Merck & Co
Neoantigen Immunotherapy for Solid Tumors: Molecular Responses & Clinical Benefit in Late-Stage Patients
Download the event guide for full session details.
Speaker
-
Andy Ferguson
Vice President, Clinical Science - Gritstone Bio
Accessing a Vast Design Space with a Modular High Throughput Platform for RNA Therapeutics & Vaccines
Download the event guide for full session details.
Speaker
-
Stephanie Khan
Director, Business Development - Ginkgo Bioworks
Quality in mRNA Therapeutics – How to Achieve this in Practice
Download the event guide for full session details.
Speaker
-
Philip Challis
Senior Vice President of Manufacturing - etehrna
Lunch Networking Break
Day One Track A, PM, Heading 1
Session 1 Day One Track A, PM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
David Richardson
SEO Influencer - Search Ltd
Supercharging the Translation of Novel mRNA Therapeutics to Combat Cancer & Advance Regenerative Medicine
Mission Possible: Showcasing Breakthrough mRNA Vaccine Initiatives to Establish Rapid Responses to Viral Pathogens
Supercharging the saRNA Vaccine Platforms Against Infectious Diseases to Improve Patient Outcomes
Advancing Novel mRNA Therapeutics Through Discovery & Development Phases
Download the event guide for full session details.
Speaker
-
Sam Deutsch
Chief Scientific Officer - Nutcracker Therapeutics
RNA Vaccine Innovations for CEPI’s 100 Days Mission
Download the event guide for full session details.
Speaker
-
Dimki Patel
CMC Program Leader - CEPI
Next Generation Self-Replicating RNA (srRNA) Drives Substantial Improvement in Infectious Disease Vaccines
Download the event guide for full session details.
Speaker
-
Nathaniel Wang
Chief Executive Officer - Replicate Bioscience
Strategies for Navigating the Complexity & Diversity of RNALipid Nanoparticles
Download the event guide for full session details.
Speaker
-
Ian Johnston
Field Application Scientist - Cytiva
Maximizing Success in mRNA Manufacturing: Key Considerations for Analytical Characterization
Download the event guide for full session details.
Speaker
-
Eunseo Ency Lee
Lead Scientist, mRNA Manufacturing Group - Samsung Biologics
mRNA-Based Transcription Factor Delivery to In Vivo Disease Models
Download the event guide for full session details.
Speaker
-
Hanae Toyonoga
Manager, Discovery Accelerator - Astellas Pharma
Session 2 Day One Track A, PM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Kevin Nguyen
Head of Business Development - Pacific Partnerships
Session 2 Day One Track B, PM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Harold Johnson
CEO - Acme Ltd
Advancing Onco-Selective mRNA Therapeutics with Kernal’s KR-335 Program to Kill Tumor Cells
Download the event guide for full session details.
Speaker
-
Manfred Kraus
Vice-President, Head of R&D Therapeutics - Kernal Biologics
BAXERNA: On a Mission to Develop Novel Bacterial mRNA Vaccines
Download the event guide for full session details.
Speaker
-
Lyudmila Kovalchuke
Project Manager - VIB-UGent
Comparing a Second-Generation saRNA Flu Vaccine with a Traditional mRNA Flu Vaccine
Download the event guide for full session details.
Speaker
-
Cheng Chang
Associate Director, RNA Platform - CSL
Afternoon Networking Break & Poster Session
Broadening the Horizons of mRNA Through Next Generation Replicating Vaccines & Therapeutics
Revealing the Latest Next Generation Infectious Disease Vaccines to Open Up New Frontiers for mRNA
Flash Poster Presentations
Improvements to the Self-AAmplifying RNA Platform for Safer & More Effective Vaccines & Therapeutics
Download the event guide for full session details.
Speaker
-
Peter Berglund
Chief Scientific Officer - HDT Bio
Beyond Respiratory mRNA Vaccines: Moderna’s Norovirus mRNA Vaccine Candidates
Download the event guide for full session details.
Speaker
-
Till Schoofs
Director, Clinical Development, Infectious Diseases - Moderna
Flash Poster Presentations
Jeffrey Ulmer, President, TechImmune LLC Rachel Young, Graduate Research Fellow, Rowan University Download the event guide for full session details.
Fine-Tuning mRNA Production with Innovative Enzymes & Raw Materials for Faster Synthesis
Diving into the Analytical Characterization of in vitro Transcribed mRNAs
Download the event guide for full session details.
Speaker
-
Julien Camperi, Ph.D.
Technical Development Principal Scientist - Gene & Cell Therapy - Genentech, A Member of the Roche Group
Presenting Johnson & Johnson’s Discovery & Pre-Clinical Work with saRNA for Vaccine & Therapeutic Applications
Download the event guide for full session details.
Speaker
-
Rachel Groppo
Director, Lead Self-Amplifying RNA Team - Johnson & Johnson Innovative Medicine
Democratizing mRNA Therapeutics with Novel Cap Analogs & Modified NTPs
Download the event guide for full session details.
Speaker
-
May Guo
Chief Commercial Officer - Areterna
Drinks Reception Hosted by Thermo Fisher
Day Two Track C, AM
Day Two Track C, AM, Heading 1
Session 1 Day Two Track C, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Emily Carter
Chief Financial Officer - Global Dynamics
Session 2 Day Two Track C, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Angela Harris
Director of Marketing - Synergy Strategies
Day Two Track C, AM, Heading 2
Session 3 Day Two Track C, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Marcus Johnson
Senior Project Manager - Innovative Solutions
Session 4 Day Two Track C, AM
Lorem ipsum dolor sit amet, consectetur adipiscing elit Mauris viverra nibh sit amet consequat mattis Donec efficitur lectus eget velit molestie, et egestas tellus tempor
Speaker
-
Sarah Lee
Chief Strategy Officer - Visionary Ventures
Day 2 AM - SPP
Morning Check In & Coffee
Chair’s Opening Remarks
Speaker
-
Emily English
Senior Vice President & Head of Manufacturing Operations - Cartesian Therapeutics
De-Risking Your Pipelines with Guidance from Regulatory Experts to Realize the Promise of mRNA
Discussing the Regulatory Expectations for mRNA-Based Therapeutics & Vaccines Against Infectious Diseases, Cancer & Rare Diseases
What are the regulatory differences between mRNA vaccines and therapeutics targeted to infectious, oncological, or rare indications? What can the next generation of mRNA vaccines and therapeutics expect as regulatory requirements? Are there any transferable regulatory learnings from mRNA vaccines and therapeutics for gene editing applications that use mRNA technology, including CRISPR?
Speaker
-
Peter Marks
Director - Center for Biologics Evaluation & Research - US Food & Drug Administration (FDA)
TFF in RNA Workflow: Process Optimization for mRNA, saRNA, & LNP Manufacturing
Delta regenerated cellulose flat sheet membranes with 100 kDa molecular weight cutoff for TFF in RNA workflows TFF optimization for mRNA, saRNA, and LNPs where a single filter can work across modalities How process conditions can impact LNP processing time Scalability data from bench (93 cm2 ) to manufacturing-scale (2.5 m2 ) using LNPs, discussing…
Speaker
-
Divakara Uppu
Lead Scientist - Cytiva
Panel Discussion : Uniting Regulatory Experts from Industry & Agencies to Navigate the Complex Landscape for mRNA-Based Medicines
How do the FDA, EMA and MHRA define a “platform” and what are the paths available to mRNA drug developers to utilize “platforms” as a way to expedite approvals Is it the right time to start developing mRNA specific regulatory guidance and should there be separate guidelines for each therapeutic area and/or application? What tools…
Speakers
-
Peter Marks
Director - Center for Biologics Evaluation & Research - US Food & Drug Administration (FDA) -
Ka-Wai Wan
Leading Senior Pharmaceutical Assessor - Medicines & Healthcare products Regulatory Agency -
Emily English
Senior Vice President & Head of Manufacturing Operations - Cartesian Therapeutics -
Nitisha Pyndiah
Director - Global Regulatory Affairs Lead - GlaxoSmithKline -
Carla Vinals
Vice President, Global Regulatory Product Strategy - Moderna -
Marco Cavaleri
Head of Anti-infectives & Vaccines - European Medicines Agency
Empowering the mRNA Industry with Nucleic Acid Therapeutics: Innovating for Success
Thermo Fisher Scientific’s extensive capabilities and tailored solutions in nucleic acid therapeutics, specifically for the mRNA industry Detailed overview of Thermo Fisher Scientific’s ability to deliver highly impactful and effective solutions in this rapidly evolving field An inspiring real-life example showcasing Thermo Fisher Scientific’s successful support for businesses in the mRNA industry, highlighting their reliability…
Speaker
-
Sara Henneman
General Manager, Nucleic Acid Therapeutics - Thermo Fisher Scientific Inc.
Morning Networking Break
Day 2 PM (ii) - SPP
Gearing up for 2025: Licensing, Partnership & Financial Considerations in the Dynamic mRNA Landscape
Wellcome Leap’s R3 Program: RNA Readiness & Response
R3: “RNA Readiness + Response” program goals and demonstrations at scale, to enable equitable access to RNA products and economically sustainable pandemic preparedness Living RNA Biofoundries based on multi-product, multi-scale, standardised manufacturing processes Demonstration on diverse RNA products and delivery systems stretch the edges of the product space Digital tools for product design and manufacturability…
Speaker
-
Duccio Medini
R3 Program Director - Wellcome Leap
Robust mRNA Production with End-to-End In-Process Analytics
Design of an efficient multi-step chromatographic process using CIMmultus re-usable columns to achieve scalable production of safe mRNA drug substance with low dsRNA, low fragments and residual DNA Deployment of fast analytical methods based on PATfix to reduce cost of drug substance production, and to optimize production and purification processes in shorter development timelines Overcoming…
Speaker
-
Tomas Kostelec
Product Manager, pDNA/RNA - BIA Separations
Planning for the Second Half of 2024: Investments, Partnerships & De-Risking Your mRNA Pipeline for 2025
Seizing opportunities for investments and partnerships in a thriving mRNA company Overcoming challenges within a turbulent funding climate for mRNA companies to gain a scientific advantage Key recommendations to avoid risks and ensure success
Speaker
-
Gad Berdugo
Managing Partner; Strategic Advisor - Explorium Capital
End of 4th mRNA-Based Therapeutics Summit 2024
Day 2 AM - Track B - Translation - SPP
Unlocking in vivo Cell Engineering Through mRNA Therapeutics Aiding the Fight Against Autoimmune & Oncological Diseases
Harnessing mRNA Technology to Unlock Cell Engineering Applications Against Solid Tumors
Introducing Factor’s proprietary platform applying mRNA to in vivo cell engineering therapeutics Transforming CAR-T cells in vivo to target solid tumors Expressing gene-editing proteins in vivo to turn “cold” tumors into “hot” tumors
Speaker
-
Matt Angel
Co-Founder, Chairman & Chief Executive Officer - Factor Bioscience Inc.
Implementation of Phase Appropriate mRNA Analytics in a Contract Testing Environment: Balancing the Development & Qualification Approach in a mRNA Program
The analytical requirements for characterization of mRNA Drug Substance and Drug Products have been defined by the USP as well as sponsor companies participating in early phase clinical trials Balancing the effort spent on method development and qualification/validation is critical to keeping with timelines and controlling analytical costs How to utilize a suite of mRNA…
Speaker
-
Jeff Heiser
Chief Scientific Officer - Microbial & Advanced Therapeutic Platforms - BA Sciences
In Vivo Induction of CD19 CAR-T Cells using mRNA as a Therapeutic for Autoimmune Indications
Describing Capstan’s LNP platform capable of extra-hepatic delivery Targeting the hematopoietic system with tolerable doses of mRNA-LNP Discussing the pre-clinical CAR-T data in mouse and NHPs using Capstan’s technology
Speaker
-
Michael Rosenzweig
Executive Vice President - Capstan Therapeutics
Day 2 AM - Track A - Discovery - SPP
Accelerating the Development of mRNA-Based Vaccines & Therapeutics to Fight Infectious & Oncological Diseases
Speaker
-
Denny Kraichely, Ph.D.
Global Program Leader - Pfizer
Advancing Immunoinformatic Tools for Epitope Mapping to Supercharge Development of mRNA-Based Personalized Cancer Vaccines
Streamlined and automated cancer vaccine design platforms are key to develop on-demand therapeutics Enhanced antigen selection enables the removal of inhibitory sequences that curtail vaccinemediated immune responses Computational vaccinology toolkit
Speaker
-
Guilhem Richard
Chief Scientific & Technology Officer, Head of Innovation & Technology - EpiVax, Inc.
Radar Therapeutics: Pioneering Precision-Expressed mRNA Therapeutics
Overview of Radar’s proprietary RNA sense-and-respond platform for precise expression of mRNA/gene therapeutics RADAR enables cell-type specific RNA expression by sensing intracellular RNA markers that define the cell type, disease state or cell state of interest to activate translation of a synthetic transcript RADAR enables precise, autonomous cell-selectivity that can bring specificity to broadly-targeting delivery…
Speaker
-
Sophia Lugo
CEO, Chairman, and Co-Founder - Radar Therapeutics
Innovac’s End-To-End Approach to Capitalize on the mRNA Revolution in the Vaccine Industry
Describing Innovac’s platform technologies and pipeline to drive the next wave of therapeutic and prophylactic mRNA vaccines Selecting and stratifying disease targets and patient populations for mRNA vaccines Revealing new pre-clinical data from multiple vaccine projects targeting infectious diseases and cancer
Speaker
-
Nicholas Valiante
CSO and Co-Founder - Innovac Therapeutics
Day 2 AM - Track C - Clinical Development- SPP
Key Clinical Case Studies on mRNA-Based Vaccines & Therapeutics Against Rare Diseases
Unveiling Moderna’s Latest Efforts to Target Rare Diseases with Protein Replacement Using mRNA Therapeutics
Introducing Moderna’s latest expansions into rare diseases with mRNA protein therapy Revealing proof of concept from early stage trials against propionic and methylmalonic acidemia, and type 1 glycogen storage disease Discussing safety data from prolonged exposure to mRNA therapeutics targeted at the above indications
Speaker
-
Kyle Holen
Head of Oncology & Therapeutics Development - Moderna
Overcoming dsRNA Challenge: Innovation in Assays & Enzymes
Optimization of IVT-PP for dsRNA is challenging Next-Generation T7: Overall performance enhanced ds-SensorTM: State-of-the-art dsRNA assay
Speaker
-
Kelly Li
R&D Manager - Vazyme
Leveraging the LUNAR® Platform to Develop RNA Medicines for Diseases with Significant Unmet Medical Needs & Accelerated Clinical Paths
Overview of the ARCT-032 program – an mRNA replacement therapy to deliver a new copy of the CFTR mRNA into CF patients’ airways Overview of the ARCT-810 Program – an mRNA medicine that enables OTC patients to make healthy functional OTC enzymes in their liver cells ARCT-154 demonstrates non-inferiority to original strain and superior immunogenicity…
Speaker
-
Sean Sullivan
Vice President, Senior Fellow & Head of Research & Technology Innovation - Arcturus Therapeutics
Day 2 AM - Track D - CMC - SPP
Deciphering Critical Quality Attributes & Embracing Next Generation Analytical Techniques for Enhanced mRNA Characterization
Understanding Critical Quality Attributes for mRNA in a Cell Therapy Setting
Review of the recent general quality guidelines for mRNA Applying the guidelines to mRNA quality in the context of a cell therapy program Strategies for analytical development, qualification and validation for mRNA in a cell therapy context
Speaker
-
Emily English
Senior Vice President & Head of Manufacturing Operations - Cartesian Therapeutics
Comprehensive Evaluation of T7 Polymerase for Enhanced Yield & Quality in mRNA Production
A high throughput screening (HTS) workflow was established to enable comprehensive evaluation of T7 polymerase as a critical raw material in mRNA production Four commercially available wild type T7 polymerases were systematically evaluated via DOE based optimizations, subsequently lot-to-lot variations, and scalability studies A deep profile of each T7 polymerases including their performance in mRNA…
Speaker
-
Jing Zhu
Director- Messenger Ribonucleic Acid, Process & Analytical Development - Recipharm
Process & Analytical Development Advances for eRNA Therapeutics
Introduction to Sail Biomedicines’ bioplatform for programmable medicines Overview of the differences between the techniques used for eRNA compared to mRNA How to align RNA analytical methods to streamline manufacturing
Speaker
-
Francis Poulin
Vice President - Analytical Sciences - Sail Biomedicines
Day 2 PM - Track C - Clinical Development- SPP
Unlocking Novel Disease Areas with Disruptive Companies Using Next Generation mRNA Therapeutics
Updates & Interim Data of mRNA-Based Cancer Vaccines to Treat EBV-Related Cancers
Presenting the latest clinical data for breakthroughs in the treatment of EBV-related cancers, including NPC and NKT lymphoma Highlighting safety and efficacy based on ongoing enrolment and interim data from clinical trials Demonstrating the transformative potential of mRNA therapeutics in the treatment of viralrelated malignancies
Speaker
-
Xiangrong Song
Chief Executive Officer & Co-Founder - WestGene Biopharma
Clinical Updates on Gene Editing Therapeutics Targeting Rare Diseases in the Liver
Introducing YolTech’s high throughput discovery platform for novel CRISPR-CAS proteins Revealing clinical trial data from the lead program targeting ATTR with a gene editing approach Revealing clinical trial data from a second program targeting PCSK9 with a gene editing approach
Speaker
-
Emma Wang
CTO - Yoltech
Day 2 PM - Track D - CMC - SPP
Upgrading Platforms Through the Latest Digital & Technological Advancements for Faster mRNA Manufacturing
Harnessing Digital Twin for mRNA Manufacturing
Mechanistic models are being constructed for all unit operations for the manufacturing of mRNA biotherapeutics The models are integrated with models for constraints, uncertainties, and disturbances to form a digital twin for integrated manufacturing The digital twin is used to analyze the comparative performance for batch and continuous manufacturing
Speaker
-
Richard Braatz
Professor & Associate Director - Faculty - Massachusetts Institute of Technology
Evolving Self-Amplifying RNA Development by Pinpointing Influences & Tailoring Manufacturing Scale
Identifying the differences in materials and piloting the process development to optimize the results Navigating the landscape of new technologies, and how to incorporate this into your program Discussing the future of self-amplifying RNA and customized therapies, and scaling processes to meet patient needs
Speaker
-
Scott Alderucci
Director - Curia Global, Inc.
Afternoon Networking Break
Day 2 PM - Track B - Translation - SPP
Enabling Improved Potency Assays for Faster & Robust Efficacy Characterization
Critical Quality Attributes: Development of a Potency Platform Assay for mRNA-Based Therapeutics & Vaccines
Current guidelines and ongoing discussions with health authorities regarding potency assay strategies Overview of existing technologies Introduction of a potency assay platform approach
Day 2 PM - Track A - Discovery - SPP
Elucidating the Fate of the mRNA Payload Inside the Cell for Increased Delivery Efficiency & Expression
Decoding the Dance: Unravelling the Moves of LNP-mRNA-based Vaccines
Understanding the Mechanism of Action of vaccines based on LNP-mRNA technology Investigating the internalization and trafficking of cellular LNP, as well as the release of RNA cargo Unravelling the Mechanism of Endosomal Escape
Speaker
-
Alisa Zhilin-Roth
Senior Scientist. Discovery Biology- In Vitro and Mechanism of Action. Center for mRNA Excellence - Sanofi
Day 1 AM - Track B - Translation - SPP
Widening the Scope of mRNA with circRNA Vaccines & Therapeutics to Treat Infectious & Oncological Diseases
Introducing Orbital’s circRNA Vaccine Platform as a Novel Alternative to a Linear Vaccine
Download the event guide for full session details.
Speaker
-
Gilles besin
Chief Scientific Officer - Orbital Therapeutics
Reduction of LNP-Associated Inflammation with Use of Biodegradable Lipids
Download the event guide for full session details.
Speaker
-
Syed Reza
Licensing & External Innovation Alliance Mangement Professional - NOF CORPORATION
In vivo panCARTM Therapy Using Circular RNA for the Treatment of B Cell Malignancies in Oncology & Autoimmune Disease
Download the event guide for full session details.
Speaker
-
Robert Mabry
Chief Scientific Officer - Orna Therapeutics
Day 1 AM - Track C - Clinical Development - SPP
Advancing Neoantigen-Based mRNA Medicines in the Clinic to Effectively Treat Oncological Indications
Speaker
-
Laureen Ojalvo
Executive Director - Oncology Medical - Moderna
Revealing Key Clinical Findings from Moderna’s Individualized Neoantigen Therapy Against Melanoma
Download the event guide for full session details.
Mitigating Risk Through Development & Engineering Runs When Transitioning from Preclinical to Clinical Manufacturing
Download the event guide for full session details.
Speaker
-
Evan Myers
Associate Director - Process Development - TriLink BioTechnologies
Neoantigen Immunotherapy for Solid Tumors: Molecular Responses & Clinical Benefit in Late-Stage Patients
Download the event guide for full session details.
Speaker
-
Andrew Ferguson
Vice President - Clinical Science - Gritstone bio, Inc.
Day 1 PM (ii) - SPP
Drinks Reception Hosted by ThermoFisher Scientific
Day 1 PM (i) - Track D - CMC - SPP
Mission Possible: Showcasing Breakthrough mRNA Vaccine Initiatives to Establish Rapid Responses to Viral Pathogens
RNA Vaccine Innovations for CEPI’s 100 Days Mission
Download the event guide for full session details.
Speaker
-
Dimki Patel
Chemistry, Manufacturing, & Controls Program Lead - CEPI
Maximizing Success in mRNA Manufacturing: Key Considerations for Analytical Characterization
Download the event guide for full session details.
Speaker
-
Eunseo Lee
Specialist & Group Lead - Samsung
BAXERNA: On a Mission to Develop Novel Bacterial mRNA Vaccines
Download the event guide for full session details.
Speaker
-
Lyudmila Kovalchuke
Project Manager - VIB-UGent Center for Medical Biotechnology
Day 1 PM (ii) - Track B - Translation - SPP
Broadening the Horizons of mRNA Through Next Generation Replicating Vaccines & Therapeutics
Speaker
-
Peter Berglund
Chief Scientific Officer - HDT Bio
Improvements to the Self-Amplifying RNA Platform for Safer & More Effective Vaccines & Therapeutics
Download the event guide for full session details.
Presenting Johnson & Johnson’s Discovery & Pre-Clinical Work with saRNA for Vaccine & Therapeutic Applications
Download the event guide for full session details.
Speaker
-
Rachel Groppo
Director - self amplifying Ribonucleic Acid team Lead - Johnson & Johnson
Day 1 PM (ii) - Track D - CMC - SPP
Flash Poster Presentations
Flash Poster Presentations
Download the event guide for full session details.
Speakers
-
Rachel Young
Graduate Research Fellow - Rowan University -
Jeffrey Ulmer
President & CEO - TechImmune
Fine-Tuning mRNA Production with Innovative Enzymes & Raw Materials for Faster Synthesis
Democratizing mRNA Therapeutics with Novel Cap Analogs & Modified NTPs
Download the event guide for full session details.
Speaker
-
May Guo
CCO - Areterna
Day 1 PM (i) - Track A - Discovery - SPP
Advancing RNA Drug Development & Design with Next-Generation Discovery Platforms
Introduction to Orna’s Proprietary IRES Discovery & Drug Design Platform for Durable & Sustainable circRNA Expression
Download the event guide for full session details.
Speaker
-
Allen Horhota
Vice President, RNA Sciences - Orna Therapeutics
Novel Efficient Cap Analogs Development & Application for mRNA Therapeutics
Download the event guide for full session details.
Speaker
-
Junlan Ren
Managing Director - Henovcom Bioscience Co.,Ltd
Development of an mRNA Platform to Fight Infectious Disease
Download the event guide for full session details.
Speaker
-
George Thom
Director - AstraZeneca
Day 1 PM (i) - Track B - Translation - SPP
Supercharging the Translation of Novel mRNA Therapeutics to Combat Cancer & Advance Regenerative Medicine
Advancing Novel mRNA Therapeutics Through Discovery & Development Phases
Download the event guide for full session details.
Speaker
-
Samuel Deutsch
Chief Scientific Officer - Nutcracker Therapeutics
mRNA-Based Transcription Factor Delivery to In Vivo Disease Models
Download the event guide for full session details.
Speaker
-
Hanae Toyonaga
Manager - Astellas Pharma
Advancing Onco-Selective mRNA Therapeutics with Kernal’s KR-335 Program to Kill Tumor Cells
Download the event guide for full session details.
Speaker
-
Manfred Kraus
Vice President & Head of Research & Development Therapeutics - Kernal Biologics Inc.
Day 1 PM (i) - SPP
Afternoon Networking Break & Poster Session
Day 1 AM - Track D - CMC - SPP
Developing a Strategic Platform Approach to Ensure Robust Manufacturing Processes for mRNA-Based Drugs
Establishing an mRNA Vaccine Platform to Effectively Support a Broad Vaccine & Therapeutics Drug Portfolio
Download the event guide for full session details.
Speaker
-
Joshua Di Napoli
Marketing & Communications Manager - Houston Methodist
Trehalose & Sucrose: Essential Components of Platform Biopharma Formulations & COVID-19 Applications
Download the event guide for full session details.
Speaker
-
Sudhakar Voruganti
Director - Pfanstiehl Inc
Leveraging Historic Know-How to Establish a Strategic Internal End-to-End Nucleic Acid Production Platform
Download the event guide for full session details.
Speaker
-
Emily Wen
Senior Principal Scientist - Merck & Co
Quality in mRNA Therapeutics – How to Achieve this in Practice
Download the event guide for full session details.
Speaker
-
Phil Challis
Senior Vice President - etherna immunotherapies NV
Day 1 PM (ii) - Track A - Discovery - SPP
Advancing Next Generation mRNA Drug Development with Optimized mRNA-LNP Platforms to Enable Targeted Delivery
Introducing ZipCode Bio’s Proprietary mRNA Medicine Platform
Download the event guide for full session details.
Shedding Light on dsRNA: Specific & Sensitive Detection Using Bioluminescence
Download the event guide for full session details.
Day 1 PM (ii) - Track C - Clinical Development - SPP
Revealing the Latest Next Generation Infectious Disease Vaccines to Open Up New Frontiers for mRNA
Beyond Respiratory mRNA Vaccines: Moderna’s Norovirus mRNA Vaccine Candidates
Download the event guide for full session details.
Speaker
-
Till Schoofs
Director Clinical Development - Moderna
Diving into the Analytical Characterization of in vitro Transcribed mRNAs
Download the event guide for full session details.
Speaker
-
Julien Camperi
Senior Principal Scientist - Gene & Cell Therapy - Genentech
Day 1 PM - SPP
Lunch Networking Break
Day 1 PM (i) - Track C - Clinical Development - SPP
Supercharging the saRNA Vaccine Platforms Against Infectious Diseases to Improve Patient Outcomes
Next Generation Self-Replicating RNA (srRNA) Drives Substantial Improvement in Infectious Disease Vaccines
Download the event guide for full session details.
Speaker
-
Nathaniel Wang
Chief Executive Officer. - Replicate Bioscience
Strategies for Navigating the Complexity & Diversity of RNALipid Nanoparticles
Download the event guide for full session details.
Speaker
-
Ian Johnston
Field Application Scientist - Cytiva
Comparing a Second-Generation saRNA Flu Vaccine with a Traditional mRNA Flu Vaccine
Download the event guide for full session details.
Focus Day PM - SPP
Afternoon Networking Break
Breakthrough Innovations Workshop Save Millions of Lives, Trillions of Dollars, and Enable Real Global Equity
The R3: RNA Readiness and Response program, took a page from the semiconductor industry transformation in the 1980s, which developed multi-product foundries with standardized processes and design tools that exploded global innovation. This session will cover R3 advances in: Manufacturing processes, with the potential for 10mg to 1kg of RNA-based product, or up to 100…
Speakers
-
Eric Smith
Director - Translational Research & Immune Effector Cell Therapies - Dana-Farber / Harvard Cancer Center -
Alexander Baron van Asbeck
Chief Executive Officer & co-founder - RiboPro -
Philip Santangelo
Professor - Winship Cancer Institute of Emory University -
Duccio Medini
R3 Program Director - Wellcome Leap -
Xavier Godron
Co-founder & Chief Technical Officer - DNA Script -
Kenta Matsuda
R&D Director - VLP Therapeutics LLC -
Robin Shattock
Professor - Imperial College London -
Harris Makatsoris
Founder - Centillion Technology Ltd.
Drinks Reception hosted by Wellcome Leap
Focus Day AM - SPP
Morning Check In & Coffee
Next Generation mRNA Delivery Day
Advancing Novel Lipid Discovery to Improve Nanoparticle Composition for Safe Systemic Delivery of LNP-mRNA
Overcoming Anti-PEG Antibody Responses to Increase Potency & Decrease Adverse Side Effects of mRNA-LNP Formulations
Speaker
-
Randall Moreadith
CDO - Serina Therapeutics, Inc.
Phospholipids in Vaccines
Speaker
-
Brian Doherty
Senior Manager - Business Development - Lipoid
AI-Assisted Design of IV-Administered Organ-Targeting LNPs for Effective Nucleic Acid Delivery to Extrahepatic Organs
Speaker
-
Daniel Quevedo
Associate Director - METiS Therapeutics
Innovating Nanoparticles Beyond LNPs to Access Specific Organs & Supercharge Your mRNA Delivery Chair: Annette Bak, Head of Drug Delivery, AstraZeneca
Crafting a Multi-Layered Nano Formulation Approach to mRNA Stabilization & Cell-Specific Delivery Using a Novel Nucleic Acid Delivery Platform
Speakers
-
Jessica Rouge
Associate Professor - University of Connecticut -
Annette Bak
Head of Advanced Drug Delivery - AstraZeneca
yEVs Enabling the High-Efficiency Introduction of Diverse Cargos, Including mRNA, Functional Antibodies, & Enzymes, to a Broad Range of Cell & Tissue Types
Speaker
-
Richard Sayre
Chief Scientific Officer - Mercury Bio
Engineering Futuristic & Next Generation Nanoplatforms for Delivery of mRNA Therapeutics: Academia-to-Industry Innova
Speaker
-
Beata Chertok
Team Lead, Delivery of Intracellular Biologics - AstraZeneca
Optimizing System Design to Increase Delivery Efficiency & Unlock Novel Therapeutic Applications of mRNA
Panel Discussion: Delving into the Latest Innovations in LNPs & Beyond for Effective Delivery of mRNA Therapeutics
Speakers
-
Annette Bak
Head of Advanced Drug Delivery - AstraZeneca -
Andrew Geall
CDO - Replicate Bioscience -
Beata Chertok
Team Lead, Delivery of Intracellular Biologics - AstraZeneca -
Allen Horhota
Vice President, RNA Sciences - Orna Therapeutics
Moving Beyond the Needle: mRNA Vaccine Delivery via Dermal, Pulmonary, & Nasal Pathways
Speaker
-
John Patton
Head SAB - Kindeva Drug Delivery
Designing Lipid Nanoparticles for mRNA Delivery to Study & Treat Diseases in Pregnancy
Speaker
-
Rachel Riley
Assistant Professor - Rowan University
Regulatory Affairs Strategy Day
Tackling mRNA CMC Challenges Through Regulatory Engagement & Platform Strategies for Faster Manufacturing
Anticipating & Planning for CMC-Related Regulatory Hurdles to Advance the Manufacturing of Next Generation mRNA Vaccines
Speaker
-
Andrew Geall
CDO - Replicate Bioscience
Roundtable Discussion: Aligning Quality Control & Regulatory Submissions for Personalized Cancer Vaccines to Get Life-Saving Drugs to Patients Faster
Speakers
-
Nazia Noor
VP Global Regulatory Affairs, CMC - BioNTech -
Hang Yuan
CTO - Innovac Therapeutics -
Ka-Wai Wan
Leading Senior Pharmaceutical Assessor - Medicines & Healthcare products Regulatory Agency
Discussing How to Engage with the EMA to Expedite mRNA Medicines to Patients Faster
Speaker
-
Marco Cavaleri
Head of Anti-infectives & Vaccines - European Medicines Agency
Building Pre-Clinical, Process, Analytical & Comparability Strategies to Create a Holistic Regulatory Package for Your mRNA Platform
Comparability – Regulatory Strategy Considerations for mRNA Product CMC Changes
Speaker
-
Nazia Noor
VP Global Regulatory Affairs, CMC - BioNTech
Planning for Success: Creating a Regulatory Strategy for the Successful Development of a Novel mRNA Platform
Speaker
-
Nitisha Pyndiah
Director - Global Regulatory Affairs Lead - GlaxoSmithKline
Engaging with the Regulatory Nuances for Different Disease Areas to Create Effective mRNA Drugs Against All Indications for All Patients
Evolving the Regulatory Landscape to Unlock the Potential of mRNA Platforms for Rare Diseases
Speaker
-
Carla Vinals
Vice President, Global Regulatory Product Strategy - Moderna
Disease-Specific & Personal: mRNA Therapy Immunogenicity Risk for Rare Diseases
Speaker
-
Anne De Groot
Founder & chief scientific officer - EpiVax, Inc.
Addressing the Differences in Regulatory Strategy for Various Batch Sizes of Personalized Cancer Vaccines
Speaker
-
Hang Yuan
CTO - Innovac Therapeutics
Day 2 PM (i) - SPP
Afternoon Networking Break
Day 2 PM - SPP
Lunch & Networking Break
Add New Dayss
Add New Seminarss
sss Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint…
Speaker
-
Add New Speaker
Project Manager - Pixel Perfect
Week 32 -2025 SSS SSS
Seminar Week 32 -2025 SSS SSS
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat…
week 45 seminar days sss
week 45 seminar sss
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat…
Speaker
-
week 45 speakers sss sss
aaa Project Manager - Digital Growth aaa
seminar day demo
seminar demos
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat…
Speaker
-
week demo speaker
Project Manager - SSS
9:00 am Seminar Week 32 -2025 SSS SSS
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Week 32 -2025 SSS SSS
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
9:00 am Seminar Week 32 -2025 SSS SSS
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.